Abstract
A sensitive sandwich enzyme-linked immunosorbent assay (ELISA) for the human tumor necrosis factor-related apoptosis-induced ligand (TRAIL)–osteoprotegerin (OPG) complex was developed by utilizing a monoclonal antibody that recognizes human soluble TRAIL as an immobilized capture component and anti-human OPG immunoglobulin G (IgG) labeled with biotin. We could quantify the TRAIL–OPG complex level (detection limit: 10 pmol/L). Employing this assay system, we demonstrated that the TRAIL–OPG complex was constitutively present in the human osteosarcoma cell lines, HOS, MG-63, and human salivary gland adnocarcinoma cell line, HSG.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
